Becton Dickinson and (BDX) Given a $260.00 Price Target at Barclays

Barclays set a $260.00 target price on Becton Dickinson and (NYSE:BDX) in a research report sent to investors on Thursday. The brokerage currently has a hold rating on the medical instruments supplier’s stock.

Several other research analysts have also recently issued reports on BDX. KeyCorp reissued a buy rating and set a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada restated a hold rating and set a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Citigroup raised their price target on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a buy rating in a research report on Wednesday, August 8th. Wells Fargo & Co raised their price target on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an outperform rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley raised their price target on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an equal weight rating in a research report on Thursday, October 4th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $254.07.

Shares of Becton Dickinson and stock traded down $1.22 during trading on Thursday, hitting $243.26. 994,866 shares of the company’s stock were exchanged, compared to its average volume of 1,182,177. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. Becton Dickinson and has a 52-week low of $209.91 and a 52-week high of $265.87. The stock has a market cap of $64.40 billion, a PE ratio of 22.09, a price-to-earnings-growth ratio of 1.44 and a beta of 1.19.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the company posted $2.40 earnings per share. The firm’s revenue was up 39.0% compared to the same quarter last year. As a group, equities analysts expect that Becton Dickinson and will post 12.28 EPS for the current year.

In other news, Director Timothy M. Ring sold 42,000 shares of Becton Dickinson and stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now owns 93,688 shares in the company, valued at $22,210,614.16. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP James C. Lim sold 5,189 shares of Becton Dickinson and stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the sale, the executive vice president now owns 13,318 shares in the company, valued at approximately $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BDX. Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of Becton Dickinson and by 17.2% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 4,760 shares of the medical instruments supplier’s stock valued at $1,140,000 after purchasing an additional 700 shares during the period. Harbour Capital Advisors LLC grew its position in shares of Becton Dickinson and by 36.0% in the second quarter. Harbour Capital Advisors LLC now owns 1,510 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 400 shares during the period. Gofen & Glossberg LLC IL grew its position in shares of Becton Dickinson and by 12.2% in the second quarter. Gofen & Glossberg LLC IL now owns 40,153 shares of the medical instruments supplier’s stock valued at $9,619,000 after purchasing an additional 4,359 shares during the period. Vigilant Capital Management LLC grew its position in shares of Becton Dickinson and by 160.5% in the second quarter. Vigilant Capital Management LLC now owns 1,305 shares of the medical instruments supplier’s stock valued at $313,000 after purchasing an additional 804 shares during the period. Finally, James Hambro & Partners acquired a new stake in shares of Becton Dickinson and in the second quarter valued at about $7,487,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: What is an Initial Public Offering (IPO)?

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply